c-Met targeted therapy of cholangiocarcinoma

Socoteanu, Matei P.; Mott, Frank E.; Alpini, Gianfranco; Frankel, Arthur E.

doi:10.3748/wjg.14.2990

Cited by 34 publications

(31 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As in most of the cancers, multiple genes are involved in molecular transformation of normal functioning liver tissue to malignant cholangiocites [19]. Reactive oxygen species produced during inflammatory processes modify DNA bases and result DNA damage.…”

Section: Pathogenesismentioning

confidence: 99%

“…The binding of RTK to their growth factors can induce homodimerize or heterodimerize of the receptors proteins and activate different molecules that encode and regulate cell diferentioation, cell proliferation, cell survial and angiogenesis [3, 19, 20, 29]. RTK appear to be considered as important protooncogenes for cholangiocarcinogenesis, being used as pharmaceutically targeted.…”

Section: Pathogenesismentioning

confidence: 99%

“…It is overexpressed especially in well-differentiated CC being liked to cell invasion, angiogenesis, and tumor differentiation/proliferation [19, 33]. Hepatocyte growth factor (HGF) regulates diverse biological responses including cells proliferation.…”

Section: Pathogenesismentioning

confidence: 99%

See 2 more Smart Citations

Molecular Markers in the Pathogenesis of Cholangiocarcinoma: Potential for Early Detection and Selection of Appropriate Treatment

et al. 2009

View full text Add to dashboard Cite

Cholangiocarcinoma (CC) is a primary malignancy that arises from cholangiocytes, the epithelial cells lining the bile duct livers. The worldwide incidence of CC is increasing and despite of combined therapeutic strategies, its prognosis remains poor. Till now surgery remains the only curative treatment modality. Over the past years, several important studies have yielded new insights into the molecular mechanisms of cholangiocarcinoma. This review focused on critical molecular player during the development from inflammation and cellular and molecular pathogenesis of this disease. The novel prophylactic and therapeutic approach deals especially the molecules involved in inflammation of cholangiocite or those related to promotion and progression of CC. The elucidation of their specific effects and interaction of this complex mechanism will accelerate the development of new biomarker for early detection and predictor factors outcome in CC.

show abstract

Section: Pathogenesismentioning

confidence: 99%

Section: Pathogenesismentioning

confidence: 99%

See 1 more Smart Citation

Molecular Markers in the Pathogenesis of Cholangiocarcinoma: Potential for Early Detection and Selection of Appropriate Treatment

et al. 2009

View full text Add to dashboard Cite

show abstract

“…HGFR signaling is implicated in a wide variety of human malignancies, including the following ones: melanoma, colon, gastric, bladder, breast, ovarian, pancreatic, kidney, liver, lung, head and neck, thyroid and prostate cancers [4,16,17,18]. Although there are a number of studies demonstrating the overexpression of c-met in breast cancer, there is no study comparing VEGF-A and HGFR expressions in a very homogenous group of patients with ductal breast carcinomas.…”

Section: Introductionmentioning

confidence: 99%

Correlation between hepatocyte growth factor receptor and vascular endothelial growth factor-A in breast carcinoma.

Gisterek

Matkowski²,

Suder³

et al. 2010

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:The aim of the study was to evaluate the prognostic value of the vascular endothelial growth factor A (VEGF-A) and hepatocyte growth factor receptor (HGFR, c-met) expressions in homogenous group of breast cancer patients. Tumor samples were collected from 98 patients with invasive ductal breast carcinoma stage II treated with primary surgery. We have observed a strong correlation between VEGF-A and c-met. No correlations were found between VEGF-A or HGFR expressions and clinical parameters (tumor size, grade, axillary lymph node status, age), 5-and 10-years DFS or OS. Our study did not reveal any prognostic value of c-met or VEGF. In addition they are not useful to separate a patients' subgroup with poor prognosis. Unlike in other authors' studies, our patients' group is very homogenous which might tribute to obtained results.

show abstract

“…Also hepatocyte growth factor (HGF) and its receptor c-Met are frequently overexpressed in CC [3,7,24]. HGF is mitogenic, and the increase in its production, along with the overexpression of its receptor, represents an autocrine mechanism to stimulate cell growth and proliferation.…”

Section: Molecular and Genetic Alterationsmentioning

confidence: 99%

Cholangiocarcinoma: from molecular biology to treatment

et al. 2015

View full text Add to dashboard Cite

Cholangiocarcinoma is a rare tumor originating in the bile ducts, which, according to their anatomical location, is classified as intrahepatic, extrahepatic and hilar. Nevertheless, incidence rates have increased markedly in recent decades. With respect to tumor biology, several genetic alterations correlated with resistance to chemotherapy and radiotherapy have been identified. Here, we highlight changes in KRAS and TP53 genes that are normally associated with a more aggressive phenotype. Also IL-6 and some proteins of the BCL-2 family appear to be involved in the resistance that the cholangiocarcinoma presents toward conventional therapies. With regard to diagnosis, tumor markers most commonly used are CEA and CA 19-9, and although its use isolated appears controversial, their combined value has been increasingly advocated. In imaging terms, various methods are needed, such as abdominal ultrasound, computed tomography and cholangiopancreatography. Regarding therapy, surgical modalities are the only ones that offer chance of cure; however, due to late diagnosis, most patients cannot take advantage of them. Thus, the majority of patients are directed to other therapeutic modalities like chemotherapy, which, in this context, assumes a purely palliative role. Thus, it becomes urgent to investigate new therapeutic options for this highly aggressive type of tumor.

show abstract

c-Met targeted therapy of cholangiocarcinoma

Cited by 34 publications

References 43 publications

Molecular Markers in the Pathogenesis of Cholangiocarcinoma: Potential for Early Detection and Selection of Appropriate Treatment

Molecular Markers in the Pathogenesis of Cholangiocarcinoma: Potential for Early Detection and Selection of Appropriate Treatment

Correlation between hepatocyte growth factor receptor and vascular endothelial growth factor-A in breast carcinoma.

Cholangiocarcinoma: from molecular biology to treatment

Contact Info

Product

Resources

About